Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Chubb
Federal Trade Commission
Queensland Health
Cerilliant
Citi
Farmers Insurance
Dow
Boehringer Ingelheim

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUSPIRONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Buspirone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00021528 Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Completed National Institute of Mental Health (NIMH) Phase 4 STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
NCT00029692 Effects of Ginseng and Ginkgo on Drug Disposition in Man Completed National Center for Complementary and Integrative Health (NCCIH) Phase 2 This study will assess the effects of ginseng and ginkgo on 1) cognitive function, 2) enzymes that process drugs, and 3) enzymes that may help prevent cancer.
NCT00053846 Buspirone in Reducing Shortness of Breath in Patients With Cancer Completed National Cancer Institute (NCI) Phase 2/Phase 3 RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
NCT00053846 Buspirone in Reducing Shortness of Breath in Patients With Cancer Completed University of Rochester Phase 2/Phase 3 RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
NCT00086112 Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. Completed Janssen, LP Phase 3 The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
NCT00086112 Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Buspirone Hydrochloride

Condition Name

Condition Name for Buspirone Hydrochloride
Intervention Trials
Anxiety Disorders 4
Major Depressive Disorder 4
Schizophrenia 3
Depression 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Buspirone Hydrochloride
Intervention Trials
Disease 17
Anxiety Disorders 9
Depressive Disorder 6
Autistic Disorder 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Buspirone Hydrochloride

Trials by Country

Trials by Country for Buspirone Hydrochloride
Location Trials
United States 97
China 7
Canada 4
Korea, Republic of 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Buspirone Hydrochloride
Location Trials
Massachusetts 9
Texas 8
Ohio 7
New York 7
California 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Buspirone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Buspirone Hydrochloride
Clinical Trial Phase Trials
Phase 4 13
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Buspirone Hydrochloride
Clinical Trial Phase Trials
Completed 33
Recruiting 12
Unknown status 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Buspirone Hydrochloride

Sponsor Name

Sponsor Name for Buspirone Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 8
Massachusetts General Hospital 6
Medical University of South Carolina 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Buspirone Hydrochloride
Sponsor Trials
Other 52
NIH 17
Industry 16
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
UBS
Accenture
Boehringer Ingelheim
Fuji
Federal Trade Commission
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.